RT Journal Article
SR Electronic
T1 Pleurectomy/decortication for malignant pleural mesothelioma: a single-centre experience
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1718
DO 10.1183/13993003.congress-2020.1718
VO 56
IS suppl 64
A1 Lawek Berzenji
A1 Dario Michaux
A1 Suresh Krishan Yogeswaran
A1 Annemie Van Breussegem
A1 Patrick Lauwers
A1 Jo Raskin
A1 Jeroen Hendriks
A1 Jan Van Meerbeeck
A1 Paul Van Schil
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/1718.abstract
AB Objective: The role and timing of surgery for malignant pleural mesothelioma (MPM) in a multimodal setting remains a controversial topic. Earlier studies suggest that pleurectomy/decortication (P/D) achieves similar or better oncological results and overall survival rates compared to extrapleural pneumonectomy. The aim of this study is to investigate outcomes in patients undergoing P/D for MPM at a single centre.Methods: Clinical and pathological characteristics of MPM patients treated by P/D between January 2013 and January 2020 were reviewed. Overall 30- and 90-day mortality and 1- and 2-year survival rates were calculated. Univariate and regression analyses of factors related to long-term survival were performed. Kaplan-Meier curves and the long-rank test were used to analyse differences between induction and adjuvant chemotherapy.Results: A total of 41 patients (31 male and 9 female) with a mean age of 65±7.8 years underwent P/D for MPM. The 30- and 90-day mortality rates were 2.5% and 5.4%, respectively. Overall 1-, and 2-year survival (OS) rates were 67.6% and 41.4%, respectively. Progressive disease occurred in 63.2% of all patients. Multiple regression analysis revealed age>70 years, asbestos exposure, T-status, N-status, tumour pathology, (neo)adjuvant therapy, postoperative morbidity, and progressive disease as significant prognostic factors (p<0.05). Prognosis was significantly better in the induction chemotherapy group compared to the adjuvant chemotherapy group (p=0.03).Conclusion: Patients treated with P/D for MPM in a multimodal setting have acceptable overall survival rates. The findings suggest that induction chemotherapy results in better OS than adjuvant chemotherapy.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1718.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).